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ABSTRACT  
Sleep problems are one of the most common non-motor symptoms of Parkinson’s disease (PD). The 
Parkinson’s disease Sleep Scale 2nd version (PDSS-2) was published in 2011 showing satisfactory clinimetric 
results. We performed an independent testing of the scale adding further information on its clinimetric 
properties.  
In this nationwide study 537 PD patients were enrolled. Besides PDSS-2, we assessed Patient’s Global 
Impression-Severity (PGI) scale on sleep disturbances, Non-motor Symptoms Scale and MDS-UPDRS. 
Following the Classical Theory of Tests we performed descriptive data analysis, factor analysis, reliability, 
validity and precision measurements. Subsequently, we evaluated cut-off value for detecting clinically 
meaningful sleep problems based on receiver operating characteristics analysis.  
Based on the PGI scale, 161 patients (30.0%) did not reported any sleep problems. Factor analysis revealed 
almost the same factor structure described by the original PDSS-2 validation study. Cronbach’s alpha was 
0.863 and all item had good item-total correlation. PDSS-2 demonstrated high convergent validity with 
Non-Motor Symptoms Scale and Clinical Global Impression-Severity and non-motor part of MDS-UPDRS, 
and divergent validity with age, gender, education-level, disease-duration and Hoehn-Yahr Stages. 
Presence of sleep problems was identified by scores >10.5 points on PDSS-2 (sensitivity: 85.3%, specificity: 
60.8%, diagnostic accuracy: 78.1%); whereas scores >19.5 points indicated marked sleep-related problems 
(specificity: 68.5%, sensitivity: 78.0%, diagnostic accuracy: 74.3%). 
Independent and cross-cultural validation of patient reported outcomes is essential to confirm or reject the 
findings obtained by the developers of the scale. Our results demonstrate that fundamental clinimetric 
properties of the PDSS-2 are satisfactory. 
   
INTRODUCTION  
Recently the non-motor symptoms (NMS) of Parkinson’s disease (PD) have been increasingly 
recognized as major burden of quality of life1, 2. Among the NMS, sleep-related problems are one of the 
most important and troublesome. Therefore, screening for sleep-problems and measuring their severity is 
of great clinical importance. However, sleep-related problems are certainly multidimensional. For example, 
sleep-disturbances in PD might equally be due to PD-related problems (e.g. troublesome nighttime OFF 
symptoms, hallucinations, rapid eye movements sleep behavioral disorder -RBD, or restless legs syndrome 
-RLS) and other issues not specific for PD (e.g. arousals caused by sleep apnea syndrome or nocturia).  
Based on the systematic review and evaluation of sleep-related rating scales by the Movement 
Disorders Society Task Force3, only a few scales were found to be appropriate for the PD population. 
Although the original Parkinson’s Disease Sleep Scale (PDSS) 4 was recommended by the MDS Task Force, 
they identified some weaknesses of the scale including the inability to specifically identify and measure 
sleep apnea, RBD and RLS problems. To overcome these disadvantages, a new scale, the Parkinson’s 
Disease Sleep Scale 2nd version (PDSS-2), was developed and published in 20115. It is composed of 15 items 
evaluating three domains. Each item has a 5 point Likert-type scale ranging from 0: “Never” to 4: “Very 
often” (except for item 1 which is reversed). Each domain consists of clusters of five questions (Motor 
symptoms at night: 4, 5, 6, 12 and 13; PD symptoms at night: 7, 9-11 and 15; and Disturbed sleep: 1-3, 8 
and 14)5. Symptoms on each domain can be scored in the range of 0-20 points; whereas, the sum of the 15 
responses gives the total score of PDSS-2 with the maximum value of 60 points and higher scores meaning 
more nocturnal disturbance.  
The PDSS-2 scale was validated on 113 PD patients in three centers in three different countries 
(United Kingdom, Germany and Austria).  Clinimetric properties of the scale were confirmed by factor 
analysis, internal consistency, test-retest reliability, convergent and discriminative validity, and precision 
analyses. Based on their findings, the authors stated that PDSS-2 was a reliable, valid, precise and 
potentially treatment-responsive tool for measuring sleep problems in PD5. Therefore, the usage of PDSS-2 
   
is recommended for screening and grading the severity of sleep problems in PD 6. Additionally, the clinical 
usefulness of PDSS-2 was also demonstrated in many clinical studies. First, PDSS-2 was utilized in a double-
blind, placebo-controlled trial assessing the efficacy of rotigotine on nocturnal disabilities7. Recently the 
responsiveness of PDSS-2 was also demonstrated after various therapeutic interventions including 
levodopa/carbidopa intestinal gel8 infusion and bilateral subthalamic deep brain stimulation9. 
The objective of the present study was to perform an independent and intercultural validation of 
the PDSS-2 following the principles of the Classical Test Theory 10.   
MATERIALS AND METHODS  
Patients 
In this nation-wide cross-sectional multicenter study 537 consecutive patients fulfilling the UK Brain 
Bank criteria for PD were enrolled in 9 centers. Each subject gave written consent in accordance with the 
ethical approval of National Ethical Committee (184/2013. 14437/2013/EKU). Each patient was examined 
by neurologists specialized in movement disorders. Portion of these patients (357/537) participated in the 
program of cultural adaptation and validation of the Movement Disorders Society-sponsored Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS)11 and Unified Dyskinesia Rating Scale12 into Hungarian.  
Patients with major neurocognitive decline were excluded from the study. Presence of dementia 
was defined as either having scores ≤125 points on Mattis Dementia Rating Scale (n=427)13 and/or scores 
≤22 points on Montreal Cognitive Assessment (n=537)14-16. Patients received their usual antiparkinsonian 
and other medication during the assessments. Subsequently, levodopa equivalent dosage calculations were 
performed17.  
Obtained rating scales 
Severity of sleep problems were globally characterized by a Patients’ Global Impression Scale (PGI) 
adjusted for sleep disturbances: no sleep problems, borderline/mild problems, moderate problems, 
marked problems and severe problems. 
   
The PDSS-2 was translated according to approved translation standards into Hungarian (NK and BF) 
and back-translated into English (PA). Subsequently the original English and the back-translated English 
versions were compared18.   
Besides PDSS-2, socio-demographic and PD-related data, the Hungarian validated versions of MDS-
UPDRS11, PDQ-3919 and Epworth Sleepiness Scales (ESS)18, 20 were obtained. As being part of the MDS-
UPDRS, the original Hoehn-Yahr Scale (HYS) was also taken to detect the overall severity of PD21. Because 
data from these scales were categorical, non-parametric tests were applied. Data were summarized at 
University of Pécs (by KH and NK). 
Descriptive data analysis 
As the items of most applied scales were ordinal variables, medians with interquartile range (IR, 
25th-75th percentiles) were calculated. Because a score of 0 means symptom-free condition, the prevalence 
of each item was based on the portion of subjects having the score >0 point on that particular item. For 
variables following the normal distribution (e.g. age, disease-duration), medians ± standard deviations (SD) 
were also calculated. 
Data quality was defined as the proportion of computable data. The criterion for acceptable amount 
of missing data is <10%22. For acceptability the floor and ceiling effect should be kept <15%23 and the 
skewness should range between -1 and +124.  
Factor analysis 
Before the structure of the scale was explored by a factor analysis, the value of Kayser-Meyer-Olkin 
measure of sampling accuracy (KMO) was calculated. A KMO>0.60 is a minimum requirement; whereas, 
KMOs >0.90 are considered as excellent for factor analysis. We accepted only those factors having an 
eigenvalue >1 and a Scree test for factor analysis. 
   
Reliability 
In the clinimetrics, reliability is the overall consistency of a measure. A measure is said to have a 
high reliability if it produces similar results under consistent conditions10. In our study the internal 
consistency was evaluated by three approaches: 
 Cronbach’s α (should be >0.70)25 
 corrected item-total correlation (should be >0.30 for each item) 
 item homogeneity coefficient (should be >0.30). 
Because the test-retest reliability of the Hungarian PDSS-2 was previously reported elsewhere26, in 
this independent validation project we did not include the assessment of the test-retest properties 
of the scale.  
Validity 
Validity of an assessment is the degree to which it measures what it is supposed to measure. 
Therefore, it corresponds to how a measurement is well-founded and accurately describes the real world10. 
In our study the construct validity was evaluated by three different methods: 
 Convergent validity: Convergent validity refers to the degree to which a measure is 
correlated with other measures that it is theoretically predicted to correlate with10. The total 
score and the subscores of PDSS-2 were compared to the PGI, Non-Motor Symptoms Scale 
(including the Sleep Subscale), MDS-UPDRS and PDQ-39. For correlation, Spearman’s rank 
correlation coefficients were calculated. The values of correlation coefficients can indicate 
weak (0-0.299), moderate (0.300-0.599) and high (0.600-1.000) association27. 
 Internal validity. The correlation between the domains (subscales) should not be too low 
(rS<0.300) or too high (rS>0.700) either28. 
 Discriminative validity. Discriminative validity tests whether concepts or measurements that 
are supposed to be unrelated are, in fact, unrelated10. It is well-known, that the prevalence 
   
and/or the severity of sleep-problems depend on age, sex29, 30, education level, disease-
duration and Hoehn-Yahr Staging31. Therefore, we tested the discriminative validity of PDSS-
2 against these factors. 
Precision 
Precision of the PDSS-2 was estimated by standard error of measurement (SEM), where the value of 
SEM should be less than the half of the standard deviation. 
Receiver operating characteristic (ROC) curve 
In order to establish a cut-off value for the total score of PDSS-2, which can reliably differentiate the 
presence or absence of sleep-related problems, we applied ROC analysis. Patients were categorized by the 
PGI value (no problems at all vs. presence of sleep-disturbances with any degree). This categorization 
served as the state variable and PDSS-2 total score as the test variable. The best cut-off value was 
estimated as the point on the ROC curve closest to the point of (0,1). It was calculated as the minimum 
value of the square root of (1-sensitivity)2+(1-specificity)2. Besides, area under the curve, specificity, 
sensitivity, positive and negative predictive values (PPV and NPV, respectively) and diagnostic accuracy 
were calculated for the best cut-off value. Subsequently, we also tried to calculate a threshold value for 
discriminating marked sleep problems from mild-moderate sleep-problems based on the PGI value (having 
marked and severe sleep problems vs. having mild and moderate sleep disturbances).  
Statistical analysis 
All statistical analyses were carried out using IBM SPSS software package (version 21, IBM Inc., 
Chicago, USA). Statistical significance level was set to 5%. Because the SPSS Suite did not have built-in 
functions for calculating positive and negative predictive values, we utilized the syntax available on the IBM 
website (http://www-01.ibm.com/support/docview.wss?uid=swg21483380, assessed on Jan 15, 2013). 
   
RESULTS  
Demographic and PD-related clinical data 
The subject population consisted of 537 non-demented PD patients. The clinical characteristics are 
demonstrated in Table 1.  
Descriptive measurements 
Based on the PGI scale, 161 patients (30.0%) did not report any sleep problems; whereas, 114 
patients (21.3%) had mild/borderline, 96 (17.9%) had moderate, 133 (24.8%) had marked and 33 (6.0%) 
had severe sleep problems (Table 1). 
Only 9 patients had a total score of 0 on PDSS-2. The prevalence of PDSS-2 items varied differently: 
Item 7 (hallucinations) had the lowest prevalence (16.9%), whereas, item 8 (nocturia) had the highest 
(88.6%, Table 2). Frequency of scores, median, 25th and 75th percentile values are shown in Table 2. Data 
quality was excellent for all PDSS-2 items (Table 3) 
Factor analysis 
The KMO value was sufficiently high (0.884) to enable a factor analysis. The Scree-test supported a 
one- or a three-factor solution explaining 28.9% and 38.9% of the variance, respectively. Using Principal 
Component Analysis extraction method with Varimax rotation, we identified almost the same factor 
structure as it was originally described (Table 4). Only item 8 “Nocturia” had somewhat different profile: It 
had almost identical loading for both “PD symptoms at night” and “Disturbed sleep” domains. 
Reliability analysis 
The value of Cronbach's α for the domains of the PDSS-2 varied between 0.715-0.748; whereas, for 
the total score it was 0.863 (Table 3). All the items reached the 0.30 threshold value for item-total 
correlation (Table 3). Item homogeneity index values were acceptable for all subdomains and the total 
score of PDSS-2. 
   
Validity and precision 
Table 5 shows the convergent validity for PDSS-2. The total score of PDSS-2 demonstrated high 
(>0.600) Spearman’s rank correlation coefficient with other scales measuring sleep (PGI, Sleep section of 
NMSS) or any closely related constructs (Non-motor Aspects of Experiences of Daily Living part of MDS-
UPDS, total score of NMSS, PDQ-39 Summary index). The internal validity for the subdomains of PDSS-2 
was acceptable (rS values in the range of 0.300-0.700, Table 5). As far as the discriminative properties were 
considered, all the domains and the total score significantly differed between males and females and 
among various age groups, education-levels, disease-duration, Hoehn-Yahr Staging and PGI groups (p<0.01 
and p<0.001, Kruskal-Wallis tests). 
The precision were acceptable for both the domains and the total score of PDSS-2 (Table 3) 
ROC analysis 
The cut-off value which best discriminated the presence of sleep disturbances from the absence 
was 10.5 points; therefore a total score ≥11 points on PDSS-2 may suggest the presence of clinically 
meaningful sleep-problems in PD. This cut-off value has sensitivity of 85.3%, specificity of 60.8%, PPV of 
83.6%, NPV of 64.1% and diagnostic accuracy of 78.1%. The area under the curve was 0.810, whereas the 
ROC analysis yielded the statistical significance level (p<0.01). 
The best cut-off value indicating the presence of marked sleep-problems was 19.5 points 
(specificity: 68.5%, sensitivity: 78.0%, PPV: 56.7%, NPV: 83.9% and diagnostic accuracy: 74.3%). 
DISCUSSION  
The aim of the present study was to develop the cross-cultural adaptation of the PDSS-2 and assess 
the fundamental clinimetric properties of the scale according to the principles of the Classical Test Theory.  
Concerning the descriptive properties, the obtained data quality was excellent and skewness was 
satisfactory for all subdomains of the scale. The ceiling effect was also negligible for all the domains of the 
PDSS-2. While the “Motor symptoms” and “PD symptoms” subscales had relatively high, the “Disturbed 
   
sleep” subdomain and the total score of the PDSS-2 had acceptable floor-effect. Although the presence of a 
high floor or ceiling effect may be an indicator for poor acceptability or faulty content validity and may also 
negatively influence the reliability and sensitivity of the measurement, we suspect other issue in the 
background. Because many patients (n=161, 30% of the examined population) did not have clinically 
meaningful sleep-problems these moderately high floor-effect values (18.3% and 18.1%) might be due the 
characteristics of the studied sample and not attributable to the scale itself. This assumption is further 
supported by the fact that the whole PDSS-2 scale (the total score) had only a negligible floor effect (1.7%).  
Based on the sufficiently high KMO value, the performed factor analysis revealed almost an 
identical factor structure reported in the original validation study of PDSS-2. We observed only one minor 
issue about item 8 called “Nocturia”. This item had almost the same loadings for both “PD symptoms at 
night” and “Disturbed sleep” domains (0.310 and 0.316, respectively). Moreover, nocturia is one of the 
most frequent phenomenon in sleep disturbances associated with PD. It can be caused by both PD-related 
and PD-unrelated problems. In some cases the PD symptoms (especially in OFF states) can produce urgency 
and dysuria as well as nocturia. However, obesity, cardiac failure, sleep apnea are the most important 
unrelated issues capable of producing nocturia32. Therefore, it is not surprising that the “Nocturia” item 
might similarly load in the “PD symptoms at night” and “Disturbed sleep” domains of PD. In our opinion, 
this issue might be considered as only a minor change from the original factor structure.  
Concerning the reliability of the scale, we obtained satisfactory results. The internal consistency of 
the PDSS-2 was acceptable with alpha indexes clearly exceeding the threshold value of 0.70. Total score 
reached an alpha value higher than 0.8 indicating its usefulness for individual comparisons. All items 
surpassed the threshold value of 0.30 for the item-correlations. Because the independent validation of 
reproducibility of PDSS-2 was reported elsewhere 26, in this study we did not evaluate the test-retest 
validity of the scale. That study demonstrated sufficiently high values for both the Intra-class and Lin’s 
Concordance Correlation Coefficients (0.782 and 0.799, respectively, for the total score of PDSS-2) 
indicating good reproducibility. 
   
As assumed, the convergent validity between the PDSS-2 and other scales measuring similar 
constructs was satisfactory. The Spearman’s rank correlation coefficients indicated high correlation with 
the PGI, the Sleep section of NMSS, the total score of NMSS and the Non-motor Experiences of MDS-UPDS. 
Similarly to the original validation study5, we also observed high correlation between PDSS-2 and PDQ-39 
Summary Index, an indicator of the contribution of sleep problems to impaired health-related quality of 
life. Similarly to the original PDSS-2 validation study, we also revealed low correlation between the PDSS-2 
(nocturnal problems) with ESS (daytime sleepiness) and neurocognitive tests.  
PDSS-2 showed satisfactory discriminative ability to differentiate based on gender, and between 
patients grouped according to age decades, education-levels, PD duration and HYS. (Table 6). 
The PDSS-2 subscales also correlated with each other to a moderate/high level into the standard 
limits for internal validity (rS=0.3-0.7, Table 5). The standard error of measurement values were suggestive 
of a high precision for all components of the scale. 
As far as the authors are aware of, only a single study is published on the cut-off value for PDSS-2 
differentiating clinically meaningful sleep disturbances. Suzuki and coworkers reported an optimal PDSS-2 
cut-off to be 14 or 15 points for identifying poor sleepers using Pittsburgh Sleep Quality Index >5 points33. 
Based on our results, total scores higher than 10 points are indicative of sleep disturbances and identify 
subjects whose problems need further investigation. This discrepancy may be due to the different cultural 
background of the study population (Japanese vs. Hungarian), number of included patients (146 vs. 537) 
and different anchors applied (Pittsburgh Sleep Quality Index vs. PGI). Because sleep habits are 
considerably variable among different cultures, we suggest that distinct cut-off scores should be validated 
for particular PD populations.  
We also calculated a threshold value for indicating the presence of marked sleep-problems. This 
additional cut-off value may be clinically useful for categorizing the degree of sleep-disturbances.   
The strength of our study is its multicenter nature involving a large population of non-demented PD 
patients. However, we also have to admit some weaknesses. A major limitation of the current validation 
   
study is the lack of polysomnography assessment (which should be regarded as better concurrent validity 
criterion). Polysomnographic data could provide interesting additional information; however, these data 
are not mandatory for performing a cross-cultural validation of an existent scale and determining the cut-
off score. Another limitation of our study is the exclusion of demented patients even though that 
cognitively impaired PD subjects may have apparently more disturbances with sleep quality. We decided to 
exclude demented patients form this study, because in our opinion severe dementia might interfere with 
the reliability of PDSS-2 data. We assumed that severely demented patients (<125 points on Mattis 
Dementia Rating Scale) might not fill the PDSS-2 forms as accurately as it should be, which might have a 
negative impact on data quality. To compensate this weakness, we tried to evaluate any possible 
relationship between the scores on neurocognitive tests and PDSS-2. However, we could not identify 
clinically meaningful correlation between the scores of MDRS and PDSS-2 (Table 5). 
CONCLUSIONS 
Patient reported outcomes and self-completed questionnaires are widely used for patient 
assessment, follow-up and making clinical decisions in both clinical practice and research. Validation of 
adapted scales is important to assure the usefulness of the instrument in the setting in which it will be 
applied. The most important indicators for the quality of a scale are the reliability, validity and 
responsiveness. Because the replication of outcomes is a highly desirable scientific need, the independent 
validation of patient reported outcomes is essential to confirm or reject the findings obtained by the 
developers of the scale. Our results demonstrate that the fundamental clinimetric properties of the 
Hungarian validated version of PDSS-2 are satisfactory and confirm those of the original study5. 
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Table 1. Clinical characteristics of the study cohort (n=537) 
Characteristics Mean±SD/number of patients Percentage 
Age 66.8±9.9  
Education years 11.8±3.3  
Sex 313 males 58.3% 
Disease-duration 8.1±7.7  
Fluctuation 200 37.2% 
Fluctuation years  5.3±4.2  
Presence of dyskinesia 198 36.8% 
Presence of Dementia  0 0.0% 
MDS-UPDRS Non-motor Aspects of EDL 14.2±7.6  
MDS-UPDRS Motor Aspects of EDL 15.5±9.2  
MDS-UPDRS Motor Examination 36.9±17.6  
MDS-UPDRS Motor Complications 4.5±3.7  
MDS-UPDRS Total Score 70.9±31.7  
Hoehn-Yahr stage I 31 5.8% 
Hoehn-Yahr stage II 302 56.2% 
Hoehn-Yahr stage III 137 25.6% 
Hoehn-Yahr stage IV 53 9.9% 
Hoehn-Yahr stage V 14 2.5% 
Non-Motor Symptoms Scale 62.7±43.9  
Montreal Cognitive Assessment (n=537) 24.2±3.4  
Mattis Dementia Rating Scale (n=427) 137.1±14.2  
PDQ-39 Summary index 25.2±15.4  
Levodopa equivalent dosage (mg) 359.7±444.7  
Without antiparkinson medication 28 5.2% 
Levodopa treatment 382 71.1% 
Dopamine agonist treatment 296 55.1% 
Levodopa and dopamine agonist combination treatment 235 43.7% 
COMT- inhibition treatment 208 38.7% 
MAO-inhibition treatment 117 21.8% 
Anticholinergic therapy 10 2.2% 
Deep brain stimulation therapy 73 13.6% 
Levodopa/carbidopa intestinal gel infusion therapy 11 2.0% 
Antipsychotic medication 11 2.0% 
Sedative medication usage 39 7.3% 
Severity of sleep disturbances –not present 161 30.0% 
Severity of sleep disturbances –borderline/mild 114 21.3% 
Severity of sleep disturbances –moderate 96 17.9% 
Severity of sleep disturbances –marked 133 24.8% 
Severity of sleep disturbances –severe 33 6.0% 
Presence of dementia was defined as having scores ≤125 points on Mattis Dementia Rating Scale and/or scores ≤22 points on Montreal Cognitive Assessment.
 Table 2. Prevalence, frequency of PDSS-2 items, domains and total score. 
Item Name of item Prevalence 
Frequency 
of score 0 
Frequency 
of score 1 
Frequency 
of score 2 
Frequency 
of score 3 
Frequency 
of score 4 
Median 
Percentile 
25th  
Percentile 
75th  
Mean SD 
1 Bed sleep quality 69.3% 165 136 118 71 47 1 0 2 1.4 1.3 
2 Difficulties falling asleep 55.5% 239 99 99 65 35 1 0 2 1.1 1.3 
3 Difficulties staying asleep 67.8% 173 90 96 95 83 2 0 3 1.7 1.5 
4 Restlessness of legs and arms at night 52.7% 254 86 90 76 31 1 0 2 1.1 1.3 
5 Urge to move legs and arms  52.0% 258 91 85 74 29 1 0 2 1.1 1.3 
6 Distressing dreams at night 45.3% 294 107 96 26 14 0 0 2 0.8 1.1 
7 Distressing hallucinations at night 16.9% 446 50 26 9 6 0 0 0 0.3 0.7 
8 Nocturia 88.6% 61 114 111 123 128 2 1 3 2.3 1.3 
9 Uncomfortable and immobility at night 48.4% 277 77 69 75 39 0 0 2 1.1 1.4 
10 Pain in arms and legs 51.0% 263 95 88 62 29 1 0 2 1.1 1.3 
11 Muscle cramps in arms and legs 58.5% 223 137 112 43 22 1 0 2 1.1 1.1 
12 Painful posturing in the morning 41.2% 316 78 71 46 26 0 0 2 0.9 1.2 
13 Tremor on waking 46.2% 289 79 68 61 40 0 0 2 1.1 1.3 
14 Tired and sleepy after waking in the 
morning 
70.6% 158 143 121 73 42 1 0 2 1.5 1.3 
15 Sn ring or difficulties in breathing 32.4% 363 80 66 17 11 0 0 1 0.6 1.0 
 PDSS Motor domain 81.7% 98     4 1 8 5.0 4.4 
 PDSS PD symptoms domain 81.9% 87     3 1 6 4.2 3.7 
 PDSS disturbed sleep domain 97.2% 15     8 4 11 8.0 4.6 
 PDSS Total score 98.3% 9     16 8 24 17.1 10.8 
 
Table 3.Acceptability, reliability and precision of the PDSS-2. 
 
Motor symptoms 
domain 
PD symptoms 
domain 
Disturbed sleep 
domain 
Total score 
Data quality (%) 100 100 100 100 
Skewness 0.773 0.811 0.353 0.568 
Ceiling effect (%) 0.2 0.2 0.2 0.2 
Floor effect (%) 18.3 18.1 2.8 1.7 
Cronbach's α 0.748 0.715 0.736 0.863 
Item-total correlation 0.389-0.678 0.339-0.649 0.355-0.532 NA 
Item homogeneity 0.320 0.400 0.390 0.490 
Mean 4.987 4.172 7.972 17.130 
Standard deviation 4.402 3.712 4.589 10.808 
Precision (standard error of measurement) 1.123 1.224 1.122 2.459 
 
 
 
Table 4. Results of the factor analysis (three-factor solution) 
Item Name of item 
Motor symptoms 
at night 
PD symptoms at 
night 
Disturbed 
sleep 
1 Bed sleep quality .151 .100 .767 
2 Difficulties falling asleep .281 .143 .698 
3 Difficulties staying asleep .148 .243 .838 
4 Restlessness of legs and arms at night .726 .271 .244 
5 Urge to move legs and arms  .785 .163 .255 
6 Distressing dreams at night .410 .317 .088 
7 Distressing hallucinations at night .218 .239 .122 
8 Nocturia -.052 .306 .316 
9 Uncomfortable and immobility at night .306 .679 .061 
10 Pain in arms and legs .480 .620 .169 
11 Muscle cramps in arms and legs .470 .614 .153 
12 Painful posturing in the morning .740 .264 .049 
13 Tremor on waking .311 .154 -.049 
14 Tired and sleepy after waking in the morning .198 .260 .491 
15 Snoring or difficulties in breathing .351 .469 .096 
Extraction Method: Principal Component Analysis. The items belonging to individual factors are highlighted by gray background. 
 
Table 5. Convergent validity and internal validity of PDSS-2. 
  PDSS Motor symptoms PDSS PD symptoms PDSS Disturbed sleep PDSS Total score 
CGI-S .418** .394** .718** .618** 
NMS I Cardiovascular .386** .357** .271** .392** 
NMS II Sleep .530** .507** .550** .627** 
NMS III Mood .433** .402** .407** .493** 
NMS IV Hallucinations .226** .272** .152** .248** 
NMS V Memory .252** .258** .210** .282** 
NMS VI Gastrointestinal .292** .316** .221** .325** 
NMS VII Urinary .262** .300** .390** .378** 
NMS VIII Sexual .041 .002 .072 .047 
NMS IX Miscellaneous  .323** .317** .239** .345** 
NMS Total .512** .502** .517** .607** 
MDS UPDRS Non-motor EDL .577** .551** .590** .683** 
MDS UPDRS Motor EDL .528** .543** .413** .582** 
MDS UPDRS Motor Examinations .290** .264** .183** .294** 
MDS UPDRS Motor Complications .426** .424** .348** .467** 
MDS UPDRS Total .503** .488** .409** .554** 
PDQ-39 Mobility .477** .493** .397** .538** 
PDQ-39 ADL .491** .452** .337** .499** 
PDQ-39 Emotional well being .498** .499** .411** .551** 
PDQ-39 Stigma .443** .330** .264** .396** 
PDQ-39 Social support .319** .325** .304** .371** 
PDQ-39 Cognition .414** .390** .301** .434** 
PDQ-39 Communication .359** .354** .273** .382** 
PDQ-39 Bodily discomfort .619** .617** .409** .640** 
PDQ 39 Summary index .621** .590** .460** .655** 
ESS Total .327** .420** .268** .388** 
Montreal Cognitive Assessment -.178 -.227 -.182 -.232 
Mattis Dementia Rating Scale -.072 -.121 -.024 -.082 
PDSS Motor 
 
.692** .526** .862** 
PDSS PD .692** 
 
.519** .844** 
PDSS disturbed .526** .519** 
 
.826** 
PDSS Total .862** .844** .826** 
 
The table reports Spearman’s rank correlation coefficients. *p<0.05. **p<0.01. ***p<0.001. Items having high correlation with PDSS-2 total score are highlighted.
Table 6. Discriminative validity of PDSS-2. 
  
Motor symptoms domain PD symptoms domain Disturbed sleep domain PDSS Total Score 
Mean Standard Deviation Mean Standard Deviation Mean Standard Deviation Mean Standard Deviation 
Sex 
Males 4.6 ± 4.0 4.0 ± 3.8 7.7 ± 4.3 16.4 ± 10.2 
Females 5.8 ± 4.6 4.8 ± 3.9 8.4 ± 4.6 18.9 ± 11.4 
Kruskal-Wallis test 0.010  0.017  0.119  0.017  
Age 
  
<50 years 3.9 ± 3.9 2.6 ± 3.1 6.5 ± 4.6 12.9 ± 10.4 
50-59 years 6.6 ± 4.5 5.2 ± 4.0 8.3 ± 4.3 20.2 ± 10.5 
60-69 years 5.0 ± 4.2 4.5 ± 3.8 8.1 ± 4.8 17.6 ± 11.1 
70-79 years 4.7 ± 4.4 3.8 ± 3.6 8.1 ± 4.6 16.6 ± 10.6 
≥80 years 4.0 ± 4.7 3.7 ± 3.6 7.7 ± 3.7 15.4 ± 10.3 
Kruskal-Wallis test 0.010 
 
0.020 
 
0.037 
 
0.007 
 
Education 
(years) 
0-8 5.8 ± 4.7 5.0 ± 3.9 8.8 ± 4.4 19.6 ± 11.1 
9-12 5.1 ± 3.9 4.4 ± 3.5 7.9 ± 4.2 17.3 ± 9.7 
>12 4.4 ± 4.2 3.6 ± 3.8 7.4 ± 4.5 15.5 ± 10.9 
Kruskal-Wallis test 0.014  0.001  0.038  0.001  
Disease 
duration 
  
<5 years 4.0 ± 4.1 3.0 ± 3.2 6.4 ± 4.7 14.4 ± 10.2 
5-9 years 5.1 ± 4.5 4.4 ± 3.9 8.2 ± 4.8 17.7 ± 11.2 
10-14 years 5.7 ± 4.3 5.0 ± 3.7 7.9 ± 4.3 18.7 ± 10.7 
≥15 years 6.1 ± 4.3 5.3 ± 3.8 8.9 ± 4.0 20.3 ± 10.0 
Kruskal-Wallis test p<0.001 
 
p<0.001 
 
0.033 
 
p<0.001 
 
HYS 
1 3.2 ± 3.2 2.5 ± 2.4 5.7 ± 3.8 11.4 ± 7.4 
2 4.3 ± 4.0 3.4 ± 3.3 7.4 ± 4.3 15.1 ± 9.8 
3 6.1 ± 4.9 5.0 ± 3.9 8.9 ± 4.7 20.0 ± 11.7 
4 6.4 ± 4.5 6.6 ± 4.3 10.1 ± 4.8 23.1 ± 10.9 
5 7.9 ± 5.1 6.1 ± 4.0 8.5 ± 5.1 22.5 ± 12.4 
Kruskal-Wallis test p<0.001 
 
p<0.001 
 
p<0.001 
 
p<0.001 
 
CGI-S 
0 2.7 ± 3.4 2.5 ± 2.8 4.1 ± 2.9 9.3 ± 7.6 
1 4.1 ± 3.8 3.4 ± 3.1 6.5 ± 3.1 14.0 ± 7.6 
2 6.0 ± 4.1 4.4 ± 3.2 9.2 ± 3.3 19.6 ± 8.3 
3 7.3 ± 4.7 6.3 ± 4.1 11.5 ± 3.6 25.1 ± 10.4 
4 8.5 ± 4.1 8.9 ± 4.2 14.4 ± 3.6 30.8 ± 9.8 
Kruskal-Wallis test p<0.001  p<0.001  0.033  p<0.001  
 
